October 20, 2014

   A Publication of the James Buchanan Brady
   Urological Institute Johns Hopkins Medical Institutions

Volume III, Winter 2007

What Matters Most to Us

Our driving focus is a simple one—moving our research discoveries to the patient's bedside, and turning our clinical observations into problems to be solved in the laboratory. We used to call this "bench-to-bedside" investigation. Now we call it "translational research." This issue of Discovery shows you some of our translational research in action.

For example:

  • A better cancer predictor: A new blood test, developed in the laboratory of Robert H. Getzenberg, our Research Director, may not only be better than the PSA test; it also has the potential to help predict how aggressive a man's prostate cancer is. We are very excited about this new blood test, called EPCA-2 (Early Prostate Cancer Antigen), and the great promise it has already shown.
  • Expectant management with curative intent: Years of research by Breakthrough: New Prostate Cancer Test is More Specific than PSA H. Ballentine Carter have helped define an entire segment of men with prostate cancer— men with low-volume, low-risk disease. Now, Drs. Carter and Christopher Warlick, in a study recently reported in the Journal of the National Cancer Institute, have shown that not all of these men need to rush into treatment right away. In fact, when these men are carefully followed, delaying prostate cancer surgery does not appear to compromise their ability to be cured.
  • The "Lance Armstrong" effect: An intriguing hypothesis, recently published in the Journal of the American Medical Association (JAMA) by three of our top investigators here at the Brady—Don Coffey, Robert Getzenberg, and Ted DeWeese —suggests that heat treatment may soon make prostate cancer cells more susceptible to treatments that we already have.
  • Genes and prostate cancer: It is has become very clear, primarily through research performed here by Bill Isaacs and Patrick Walsh, that there are many inherited components that, along with environmental factors, largely determine which men will develop prostate cancer. It is also clear that no single gene or piece of DNA is responsible for this inherited risk. For the first time, Dr. Isaacs' group has demonstrated systematically the identification of many genes which may increase the risk for prostate cancer and could potentially be inherited along family lines. We are extremely excited about the unprecedented insight into the genetic mechanisms responsible for prostate cancer that these efforts will yield. So much is happening here, every day— much more than we can cover in just these few pages. As always, all of our research is dedicated to you, our patients, and your families.

 

 

© Copyright 2014 | All Rights Reserved | Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287